The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

By G. Scagliotti, N. Hanna, F. Fossella, K. Sugarman, J. Blatter, P. Peterson, L. Simms, F. Shepherd. The Oncologist, 2009

714 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. (2013, background): “The recent EURTAC (European Tarceva versus Chemotherapy) study using erlotinib in European patients6 and our study using afatinib in patients from around the world clearly support initial EGFR TKI treatment in patients with EGFR mutation–positive NSCLC, regardless of race.”
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, methodology): “restricted to NSCC in any line of treatment in advanced disease [II, A] [119, 120].”
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, methodology): “An analysis of the efficacy of pemetrexed based on histology was conducted similar to the one performed in the first-line trial, albeit retrospectively and with fewer patients.(104) (Note: The publication was outside the date parameters of the systematic review.”